Multiple Myeloma — Trials

Multiple Myeloma — Trials · CancerIndex

Clinical trials

Registered studies

3,384 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 814
Recruiting: 414
Ph III recruiting: 54
Growth YoY: +13.3%
Industry share: 29%
Top sponsor: National Cancer Institute (NCI)
Termination share: 34%
Trials / 1,000 deaths: 70.3 USA 2023 cdc-uscs

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (536)

clinicaltrialsPublishedShowing 101–150 of 516 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT05714839	A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments(DynaMMic-1)	recruiting	Phase 1 / Phase 2	123	GlaxoSmithKlineINDUSTRY	13	Aug 19, 2026	clinicaltrials
NCT06106945	AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Multiple Myeloma	recruiting	Phase 1 / Phase 2	226	AstraZenecaINDUSTRY	9	Aug 19, 2026